San Francisco-based Xcell Biosciences and Thermo Fisher Scientific are collaborating to advance research in regulatory T cells (Tregs) and tumor-infiltrating lymphocytes (TILs).
Specifically, the partnership aims to advance Treg and TIL cell therapies that specialize in combating autoimmune and solid tumor diseases. The joint research will focus on developing new methodologies to enhance the efficacy of Tregs and TILs in therapeutic applications.
The collab also seeks to streamline workflows while improving scalability and reproducibility in cell therapy manufacturing to help make these critical treatments more accessible to patients. Xcellbio will utilize Thermo Fisher’s Gibco CTS Detachable Dynabeads platform within the company’s modular, closed and automated cell therapy manufacturing workflow. The partners will also leverage Xcellbio's AVATAR cell therapy manufacturing platform to enhance performance and safety of therapies.
With solid tumors representing approximately 90% of adult cancers and instances of autoimmune diseases on the rise worldwide, the collaboration looks to target a crucial area for improving global health.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!